News

June 7, 2018

Cerdulatinib Shows Promising Phase 2a Trial Results in Blood Cancer Patients, Including NHL

News

Portola Pharmaceuticals‘ investigative therapy cerdulatinib is effective and well-tolerated in patients with several types of blood cancer, including non-Hodgkin’s lymphoma, who failed multiple prior therapies, according to interim results of ... Read more

June 6, 2018

Phase 3 Trial to Test Yescarta as Second-line Therapy for DLBCL Patients

News

Kite Pharma has opened a new Phase 3 clinical trial to investigate the effectiveness of Yescarta (axicabtagene ciloleucel) as a second-line therapy for patients with relapsed or refractory diffuse large B-cell lymphoma ... Read more

June 5, 2018

Phase 2 Data Continues to Support Remetinostat in Easing Itching in Early Stage Mycosis Fungoides

News

Topical remetinostat gel significantly reduces itching in patients with a kind of cutaneous T-cell lymphoma called mycosis fungoides, data from a Phase 2 trial shows. The medicine also reduced the ... Read more

June 4, 2018

Alexo Begins Testing ALX148 Combinations in Phase 1 Trial of NHL, Solid Tumors

News

Alexo Therapeutics has started treating patients in the combination part of its Phase 1 trial, which will test multiple combinations of ALX148 with targeted antibody therapies — including Keytruda (pembrolizumab), Herceptin ... Read more

June 1, 2018

CAR T-cell Therapy JCAR017 Shows Sustained Anticancer Response in Aggressive B-Cell Lymphoma, Trial Update Reports

News

Treatment with the CAR T-cell therapy JCAR017 (lisocabtagene maraleucel, or liso-cel) provided a durable reduction or eradication of cancer in patients with aggressive forms of B-cell non-Hodgkin’s lymphoma (NHL), long-term ... Read more

May 31, 2018

Xalkori Named Breakthrough Therapy for Difficult-to-Treat Rare Lymphoma

News

The U.S. Food and Drug Administration granted breakthrough therapy designation to Pfizer’s Xalkori (crizotinib) for the treatment of a subgroup of difficult-to-treat systemic anaplastic large cell lymphoma (ALCL). The FDA’s ... Read more

May 30, 2018

Atara’s Tab-cel Shows Promise for Treating Transplant-derived Lymphoma, Trial Data Shows

News

Atara Biotherapeutics’s investigative therapy Tab-cel (tabelecleucel) is a potentially safe and viable option to treat transplant-derived lymphoma, according to long-term data from two Phase 2 clinical trials. The new results will ... Read more

May 29, 2018

Arzerra-Bendamustine Combo Fails to Delay Disease Worsening in Indolent Non-Hodgkin’s Lymphoma Patients in Phase 3 Trial

News

Adding Arzerra (ofatumumab) to the chemotherapy agent bendamustine did not delay disease progression or death in indolent non-Hodgkin’s lymphoma patients whose disease failed to respond to Rituxan (rituximab) treatment, according to a ... Read more

May 25, 2018

Revlimid-Rituxan Combo Could Replace Chemo as Follicular Lymphoma Therapy, Phase 3 Trial Suggests

News

A combination of Rituxan (rituximab) and Revlimid (lenalidomide) is similarly effective and has a better safety profile than the standard first-line regimen — chemotherapy and Rituxan — for follicular lymphoma patients, a Phase 3 ... Read more

May 24, 2018

New Collaboration will Study Long-term Outcomes of CAR T-cell Therapy Yescarta

News

The Center for International Blood and Marrow Transplant Research (CIBMTR) and Kite Pharma recently agreed to collaborate on tracking long-term outcomes of patients treated with Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor ... Read more